MedPath

Reviva Presents Positive Speech Latency Data for Brilaroxazine in Schizophrenia from Phase 3 RECOVER Trial

• Reviva Pharmaceuticals announced positive speech latency data for brilaroxazine in schizophrenia from the Phase 3 RECOVER trial. • The data will be presented as a poster at the CNS Summit 2024 in Boston, Massachusetts, on November 12th. • The presentation will highlight how enrichment based on speech latency enhances treatment effects with brilaroxazine. • Brilaroxazine is a new chemical entity being developed by Reviva for central nervous system disorders.

Reviva Pharmaceuticals is set to present positive speech latency data for its drug candidate, brilaroxazine, in the treatment of schizophrenia. The data originates from the Phase 3 RECOVER trial and will be shared at the CNS Summit 2024, held in Boston, Massachusetts, from November 10-13.
The poster presentation, titled "Enrichment Based on Speech Latency Enhances Treatment Effects in a Phase III Study of Brilaroxazine," will take place on Tuesday, November 12th, from 5:00 - 7:00 PM ET. Dr. Jan Sedway from WCG Clinical will be presenting the data.
Reviva Pharmaceuticals is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases. Their pipeline includes brilaroxazine (RP5063) and RP1208, both new chemical entities discovered in-house. The company holds composition of matter patents for both drugs in the United States, Europe, and other countries.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Reviva's Brilaroxazine Shows Sustained Efficacy and Safety in Schizophrenia Patients Over One Year

Reviva Pharmaceuticals' brilaroxazine demonstrated sustained efficacy and a favorable safety profile over one year in patients with schizophrenia in the Phase 3 RECOVER study's open-label extension (OLE).
The OLE study, involving 435 patients, showed that once-daily brilaroxazine at doses of 15mg, 30mg, and 50mg led to significant improvements in PANSS total scores and positive/negative symptoms.

Reviva Presents Positive Brilaroxazine Data on Speech Latency in Schizophrenia from Phase 3 RECOVER Trial

Reviva Pharmaceuticals announced positive speech latency data for brilaroxazine in schizophrenia from the Phase 3 RECOVER trial.
The data will be presented as a poster at the CNS Summit 2024 in Boston, highlighting the drug's potential in improving speech-related challenges.

Reviva Pharma's Brilaroxazine Shows Positive Speech Latency Data in Phase 3 Schizophrenia Trial

Reviva Pharmaceuticals will present positive speech latency data for brilaroxazine in schizophrenia from the Phase 3 RECOVER trial at the CNS Summit 2024.
The study, titled 'Enrichment Based on Speech Latency Enhances Treatment Effects in a Phase III Study of Brilaroxazine', highlights enhanced treatment effects.

Antengene to Present Selinexor Data from Phase III Multiple Myeloma and Phase I/II Lymphoma Studies at ASH 2024

Antengene will present Phase III results of weekly selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in Chinese patients with relapsed/refractory multiple myeloma.
Preliminary results from a Phase I/II study of selinexor combined with tislelizumab in relapsed/refractory extranodal NK/T-cell lymphoma will also be presented.

Teva's TEV-'749 Shows Promise in Improving Social Functioning in Schizophrenia Patients

Teva's TEV-'749, a subcutaneous olanzapine injection, demonstrated significant improvements in social functioning and quality of life in schizophrenia patients in the Phase 3 SOLARIS trial.
The SOLARIS trial showed statistically significant improvements in Personal and Social Performance Scale scores with TEV-'749 compared to placebo (p<0.05) across multiple doses.

Teva's TEV-'749 Shows Promise in Improving Social Functioning in Schizophrenia Patients

Teva's TEV-'749, a subcutaneous long-acting injectable olanzapine, demonstrated significant improvements in social functioning and quality of life in adults with schizophrenia in the Phase 3 SOLARIS trial.
The SOLARIS trial showed statistically significant improvements in the Personal and Social Performance Scale and Schizophrenia Quality of Life Scores compared to placebo.

Anavex's ANAVEX3-71 Shows Promise in Schizophrenia Phase 2 Trial with EEG Biomarker Improvements

Anavex Life Sciences reports positive preliminary results from its Phase 2 trial of ANAVEX3-71 in schizophrenia, showing dose-dependent effects on EEG biomarkers.
The trial demonstrated that ANAVEX3-71 improved 40 Hz Auditory Steady-State Response (ASSR) Inter Trial Coherence (ITC) and Resting State Alpha Power compared to placebo.

Reviva Pharmaceuticals' Brilaroxazine Shows Positive Phase 3 Results for Schizophrenia Treatment

Reviva Pharmaceuticals reported positive Phase 3 trial results for Brilaroxazine in schizophrenia, meeting the primary endpoint with a statistically significant reduction in PANSS total score.
Brilaroxazine, a serotonin-dopamine activity modulator (SDAM), demonstrated a 10.1-point reduction in PANSS score compared to placebo (p<0.001) at week four in the Phase 3 trial.

Biohaven Announces Topline Results of Troriluzole Trial in Spinocerebellar Ataxia

Biohaven's Study BHV4157-206-RWE assessed troriluzole's effectiveness in treating Spinocerebellar Ataxia (SCA) under FDA guidance.
Troriluzole is a novel glutamate modulator designed to reduce synaptic glutamate levels by enhancing glutamate uptake in glial cells.

Neurocrine's NBI-1117568 Shows Promise in Phase II Schizophrenia Trial

Neurocrine Biosciences' NBI-1117568 met its primary endpoint, significantly reducing schizophrenia symptoms at a 20mg daily dose.
The Phase II trial demonstrated a statistically significant 7.5-point placebo-adjusted mean reduction in PANSS total score.

Reference News

[1]
Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the ...
biospace.com · Nov 6, 2024

Reviva Pharmaceuticals to present positive speech latency data for brilaroxazine in schizophrenia at CNS Summit 2024 on ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy